BACKGROUND AND PURPOSE: Mechanisms of early neurologic deterioration after treatment with intravenous, recombinant, tissue-type plasminogen activator (IV rt-PA) include symptomatic intracerebral hemorrhage (SICH) and early recurrent ischemic stroke. We observed a number of cases of acute deterioration due to recurrent ischemic events. METHODS: We undertook a single-center, retrospective analysis of consecutive acute stroke patients treated with IV rt-PA between January 2006 and December 2008 to define the incidence of early neurologic deterioration (>or=4-point drop on the National Institutes of Health Stroke Scale within 72 hours) and its mechanism. Deterioration was attributed to SICH when associated with a PH1 or PH2 hemorrhage on postdeterioration computed tomography scans, to recurrent ischemic stroke when there was clinical and radiologic evidence of a new territorial infarction or new vessel occlusion, and otherwise to evolution of the incident stroke. RESULTS: Of 228 consecutive IV rt-PA-treated patients, 34 (15%) developed early neurologic deterioration, 18 (8%) secondary to incident strokes 10 (4.4%) due to SICH, and 6 (2.6%) due to early recurrent ischemic events, which were significantly associated with atrial fibrillation (present in 5 of 6 patients; 4 paroxysmal, 1 permanent). In 4 patients, sudden clinical deterioration developed during or shortly after IV rt-PA infusion, and in 2, deterioration developed 3 days later. All died 2 days to 2 weeks later. The single case without atrial fibrillation had a recurrent, contralateral, middle cerebral artery stroke during IV rt-PA infusion and multiple high-signal emboli detected by transcranial Doppler. Early recurrent ischemic stroke accounted for 5 of 12 (42%) cases of early neurologic deterioration in patients with atrial fibrillation. CONCLUSIONS: In this single-center series, the incidence of early recurrent ischemic stroke after IV rt-PA was 2.6% and was associated with previous atrial fibrillation.
BACKGROUND AND PURPOSE: Mechanisms of early neurologic deterioration after treatment with intravenous, recombinant, tissue-type plasminogen activator (IV rt-PA) include symptomatic intracerebral hemorrhage (SICH) and early recurrent ischemic stroke. We observed a number of cases of acute deterioration due to recurrent ischemic events. METHODS: We undertook a single-center, retrospective analysis of consecutive acute strokepatients treated with IV rt-PA between January 2006 and December 2008 to define the incidence of early neurologic deterioration (>or=4-point drop on the National Institutes of Health Stroke Scale within 72 hours) and its mechanism. Deterioration was attributed to SICH when associated with a PH1 or PH2 hemorrhage on postdeterioration computed tomography scans, to recurrent ischemic stroke when there was clinical and radiologic evidence of a new territorial infarction or new vessel occlusion, and otherwise to evolution of the incident stroke. RESULTS: Of 228 consecutive IV rt-PA-treated patients, 34 (15%) developed early neurologic deterioration, 18 (8%) secondary to incident strokes 10 (4.4%) due to SICH, and 6 (2.6%) due to early recurrent ischemic events, which were significantly associated with atrial fibrillation (present in 5 of 6 patients; 4 paroxysmal, 1 permanent). In 4 patients, sudden clinical deterioration developed during or shortly after IV rt-PA infusion, and in 2, deterioration developed 3 days later. All died 2 days to 2 weeks later. The single case without atrial fibrillation had a recurrent, contralateral, middle cerebral artery stroke during IV rt-PA infusion and multiple high-signal emboli detected by transcranial Doppler. Early recurrent ischemic stroke accounted for 5 of 12 (42%) cases of early neurologic deterioration in patients with atrial fibrillation. CONCLUSIONS: In this single-center series, the incidence of early recurrent ischemic stroke after IV rt-PA was 2.6% and was associated with previous atrial fibrillation.
Authors: James E Siegler; Karen C Albright; Alexander J George; Amelia K Boehme; Michael A Gillette; Andre D Kumar; Monica Aswani; Sheryl Martin-Schild Journal: Med Student Res J Date: 2017
Authors: Hannah J Irvine; Thomas Wk Battey; Ann-Christin Ostwaldt; Bruce Cv Campbell; Stephen M Davis; Geoffrey A Donnan; Kevin N Sheth; W Taylor Kimberly Journal: Int J Stroke Date: 2016-07-09 Impact factor: 5.266
Authors: Han Soo Yoo; Young Dae Kim; Hye Sun Lee; Dongbeom Song; Tae Jin Song; Byung Moon Kim; Dong Joon Kim; Dong Ik Kim; Ji Hoe Heo; Hyo Suk Nam Journal: J Stroke Date: 2013-09-27 Impact factor: 6.967
Authors: Justyna M Derbisz; Marcin Wnuk; Tadeusz Popiela; Jeremiasz Jagiełła; Roman Pułyk; Joanna Słowik; Tomasz Dziedzic; Wojciech Turaj; Agnieszka Słowik Journal: Pol J Radiol Date: 2021-06-11
Authors: Luciano A Sposato; Valeria Salutto; Diego E Beratti; Paula Monti; Patricia M Riccio; Claudio Mazia Journal: Case Rep Vasc Med Date: 2013-08-06